DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting
March 26 2021 - 4:30PM
DBV Technologies Announces a New Chair of its Audit Committee and
Date of its Annual General Meeting
Montrouge, France, March 26, 2021
DBV Technologies Announces a New Chair
of its Audit Committee and Date of its Annual General
Meeting
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, announced today that Ms. Viviane Monges,
director and member of the Audit Committee of the Board of
Directors, was appointed as Chairperson of the Board’s Audit
Committee in replacement of Ms. Claire Giraut effective March 23,
2021.
Ms. Monges has been a member of DBV
Technologies’ Board and Audit Committee since May 2019. Ms. Monges
currently serves on the Board of Novo Holdings in Denmark, Union
Chimique Belge (UCB) in Belgium, Idorsia Pharmaceuticals in
Switzerland, and Voluntis SA in France. Earlier in her career, Ms.
Monges served in several financial leadership positions at Wyeth
Pharmaceuticals, Novartis OTC, Galderma and most recently as CFO of
Nestlé’s Business Excellence Division.
Ms. Giraut has served as a member of Company’s
Board of Directors since June 2016 and as the Chairperson of the
Board’s Audit Committee since December 2016.
“On behalf of all Board members, the Company’s
management team, and shareholders, I thank Claire for her
professionalism, expertise, and the commitment with which she has
chaired the Audit Committee of DBV Technologies. We appreciate her
many contributions and wish her well,” said Michel de Rosen,
Chairman of DBV Technologies’ Board of Directors. “We welcome
Viviane to this new role as Chair of the Audit Committee and look
forward to working with her in this capacity. Viviane’s financial
acumen and experience will continue to bring invaluable insight to
DBV Technologies.”
DBV Technologies and the Board are finalizing
the appointment of a new independent director to fill the current
vacancy and to join the Audit Committee of the Board. Any such
appointment will be provisional and will be submitted to a
shareholder vote at the Ordinary and Extraordinary General Meeting
that DBV Technologies will convene on May 19, 2021. Details and
procedures with respect to DBV Technologies’ Ordinary and
Extraordinary General Meeting will be communicated by the Company
at a later date.
About DBV Technologies DBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV Technologies’ method of delivering biologically active
compounds to the immune system through intact skin. With this new
class of non-invasive product candidates, the Company is dedicated
to safely transforming the care of food allergic patients. DBV
Technologies’ food allergies programs include ongoing clinical
trials of Viaskin Peanut. DBV Technologies has global headquarters
in Montrouge, France and offices in Bagneux, France, and North
American operations in Summit, NJ and New York, NY. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing one-half of one ordinary share)
are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward-Looking StatementsThis
press release may contain forward-looking statements, including
statements regarding Company’s anticipated appointment of a new
director and such director’s independence and eligibility to serve
on the Audit Committee of Company’s Board of Directors. These
forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. Among
the factors that could cause actual occurrences to differ
materially from those described or projected herein include
uncertainties related to the availability, qualifications, and
independence of candidates to serve as director. A further
discussion of risks and uncertainties that could cause actual
results to differ materially from those set forth in the
forward-looking statements in this press release can be found in
DBV Technologies’ regulatory filings with the French Autorité des
Marchés Financiers, DBV Technologies’ filings and reports with the
U.S. Securities and Exchange Commission, including in DBV
Technologies’ Annual Report on Form 10-K for the year ended
December 31, 2020, and future filings and reports by DBV
Technologies. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements and
estimates, which speak only as of the date hereof. Other than as
required by applicable law, DBV Technologies undertakes no
obligation to update or revise the information contained in this
Press Release.
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologies+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Apr 2023 to Apr 2024